Two-Minute COVID-19 Test Uses Nanosensor Technology to Detect Presence of SARS-CoV-2 Infection in Blood at POC
|
By LabMedica International staff writers Posted on 16 Jul 2021 |

Image: Two-Minute COVID-19 Test Uses Nanosensor Technology to Detect Presence of SARS-CoV-2 Infection in Blood at POC (Photo courtesy of NanoDx, Inc.)
A SARS-CoV-2 testing system addresses existing diagnostic challenges by providing a rapid assessment from a nasal, throat, saliva, or finger stick of blood sample in a two minute test.
The simple, low-cost system that includes a portable handheld, analyzer, disposable cartridges and secure software for seamless systems integration has been developed by NanoDx, Inc. (Boston, MA, USA). NanoDx is licensing IBM Research’s (Yorktown Heights, NY, USA) nanoscale sensor technology for use in its diagnostic platform. IBM’s technology was developed with the goal of advancing sensor metal-oxide semi-conductive (CMOS) technology.
NanoDx plans to use this sensor technology for diagnostic platforms designed to provide rapid, accurate and inexpensive detection of different diseases. NanoDx also plans to use this technology to advance efforts to diagnose a variety of medical conditions rapidly and accurately, including COVID-19, different forms of influenza, traumatic brain injury (TBI), sepsis and stroke in the field of in vitro diagnostics, as well as biosensors. The IBM-designed nano biosensors are CMOS-compatible, which means they may be more cost-effectively and rapidly manufactured in high-volume. When integrated with automation circuitry, these tiny sensors may enable NanoDx’s real-time, point-of-care diagnostics technology to detect and quantify biomarkers from small fluid specimens in less than two minutes.
NanoDx is commercializing its real-time, point-of-care diagnostics platform and has built an extensive intellectual property portfolio around its nanosensor design and manufacturing processes that encompasses the entire field of in vitro diagnostics. The NanoDx System for SARS-CoV-2 is pursuing FDA Emergency Use Authorization to expand rapid COVID-19 testing.
"The field of diagnostics has changed rapidly during the past year with the emergence of COVID-19," said Sharad Joshi, President and Chief Executive Officer of NanoDx. "This global pandemic has further highlighted the need for a convenient, fast and accurate diagnostic so proper treatments can be delivered to patients as quickly as possible with the goal of shortening recovery times. As we move forward, our access to IBM's technology in the in vitro diagnostics and biosensor fields will enable us to pursue developing a high throughput diagnostics platform at a significantly lower cost."
"Our work with NanoDx is another example of IBM's collaborative approach to what we call 'hard tech': solving the deep technical problems that affect our everyday lives," said Mukesh Khare, Vice President, Hybrid Cloud Research at IBM Research. "Notably, this CMOS-compatible device can be manufactured in an existing foundry, providing easily scalable and cost-effective hardware. The integration of this technology design with NanoDx's highly-advanced nanosensor platform can help accelerate the ability to bring an extensive array of diagnostic solutions to market."
Related Links:
NanoDx, Inc.
IBM Research
The simple, low-cost system that includes a portable handheld, analyzer, disposable cartridges and secure software for seamless systems integration has been developed by NanoDx, Inc. (Boston, MA, USA). NanoDx is licensing IBM Research’s (Yorktown Heights, NY, USA) nanoscale sensor technology for use in its diagnostic platform. IBM’s technology was developed with the goal of advancing sensor metal-oxide semi-conductive (CMOS) technology.
NanoDx plans to use this sensor technology for diagnostic platforms designed to provide rapid, accurate and inexpensive detection of different diseases. NanoDx also plans to use this technology to advance efforts to diagnose a variety of medical conditions rapidly and accurately, including COVID-19, different forms of influenza, traumatic brain injury (TBI), sepsis and stroke in the field of in vitro diagnostics, as well as biosensors. The IBM-designed nano biosensors are CMOS-compatible, which means they may be more cost-effectively and rapidly manufactured in high-volume. When integrated with automation circuitry, these tiny sensors may enable NanoDx’s real-time, point-of-care diagnostics technology to detect and quantify biomarkers from small fluid specimens in less than two minutes.
NanoDx is commercializing its real-time, point-of-care diagnostics platform and has built an extensive intellectual property portfolio around its nanosensor design and manufacturing processes that encompasses the entire field of in vitro diagnostics. The NanoDx System for SARS-CoV-2 is pursuing FDA Emergency Use Authorization to expand rapid COVID-19 testing.
"The field of diagnostics has changed rapidly during the past year with the emergence of COVID-19," said Sharad Joshi, President and Chief Executive Officer of NanoDx. "This global pandemic has further highlighted the need for a convenient, fast and accurate diagnostic so proper treatments can be delivered to patients as quickly as possible with the goal of shortening recovery times. As we move forward, our access to IBM's technology in the in vitro diagnostics and biosensor fields will enable us to pursue developing a high throughput diagnostics platform at a significantly lower cost."
"Our work with NanoDx is another example of IBM's collaborative approach to what we call 'hard tech': solving the deep technical problems that affect our everyday lives," said Mukesh Khare, Vice President, Hybrid Cloud Research at IBM Research. "Notably, this CMOS-compatible device can be manufactured in an existing foundry, providing easily scalable and cost-effective hardware. The integration of this technology design with NanoDx's highly-advanced nanosensor platform can help accelerate the ability to bring an extensive array of diagnostic solutions to market."
Related Links:
NanoDx, Inc.
IBM Research
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreMolecular Diagnostics
view channel
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more








